

Pavblu[™] (aflibercept-ayyh) – New biosimilar launch

- On October 30, 2024, [Amgen launched Pavblu \(aflibercept-ayyh\)](#), biosimilar to Regeneron's [Eylea[®] \(aflibercept\)](#).
 - Pavblu is available as a 2 mg (0.05 mL of 40 mg/mL) solution in a single-dose vial and single-dose prefilled syringe.
- The [FDA approved](#) Pavblu in August 2024 for the treatment of:
 - Neovascular (wet) age-related macular degeneration
 - Macular edema following retinal vein occlusion
 - Diabetic macular edema
 - Diabetic retinopathy.
- Eylea is also approved for the treatment of retinopathy of prematurity.